Zoledronic Acid–Induced Interface Dermatitis

Zoledronic Acid–Induced Interface Dermatitis

Zoledronic acid (ZA) is a bisphosphonate given intravenously, most commonly for the treatment of postmenopausal osteoporosis. Increase in usage of ZA because it was FDA-approved has resulted in increasing reports of side effects. For the most part, these are systemic. Cutaneous side effects associated with ZA are infrequent and limited to 2 reports of dermatomyositis to date. In both, patients ...

A clinicopathological study of interface dermatitis.

BACKGROUND Interface dermatitis (ID) refers to a pattern of skin reaction characterized by an inflammatory infiltrate that appears to obscure the dermo-epidermal junction when observed at low power examination and referred to as lichenoid tissue reaction. A wide range of inflammatory skin diseases exhibits interface change with considerable overlap of histological features. The aim of the prese...

Zoledronic acid and angiogenesis.

To the Editors: In a recent issue of Clinical Cancer Research, Santini and co-workers (1) assert that zoledronic acid (ZA) may inhibit several antiangiogenic-related cascades and its metronomic administration could represent a new potential therapy targeting the endothelial-tumor-stroma behavior. We agree with the authors because better targeting of ZA to cells outside bone could more likely be...

Zometa, INN-zoledronic acid

Atopic dermatitis: allergic dermatitis or neuroimmune dermatitis?*

Advances in knowledge of neurocellulars relations have provided new directions in the understanding and treatment of numerous conditions, including atopic dermatitis. It is known that emotional, physical, chemical or biological stimuli can generate more accentuated responses in atopic patients than in non-atopic individuals; however, the complex network of control covered by these influences, e...